BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30674340)

  • 1. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
    Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
    J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
    Zheng H; Yang L; Kang Y; Chen M; Lin S; Xiang Y; Li C; Dai X; Huang X; Liang G; Zhao C
    Mol Carcinog; 2019 Apr; 58(4):565-576. PubMed ID: 30520143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
    Zhuang Y; Bai Y; Hu Y; Guo Y; Xu L; Hu W; Yang L; Zhao C; Li X; Zhao H
    Onco Targets Ther; 2019; 12():5281-5291. PubMed ID: 31308698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
    Lu YY; Jing DD; Xu M; Wu K; Wang XP
    World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling.
    Yue Y; Qian W; Li J; Wu S; Zhang M; Wu Z; Ma Q; Wang Z
    Cancer Lett; 2020 Feb; 471():135-146. PubMed ID: 31811906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway.
    Yang L; Li J; Xu L; Lin S; Xiang Y; Dai X; Liang G; Huang X; Zhu J; Zhao C
    Cancer Manag Res; 2019; 11():1167-1176. PubMed ID: 30774444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM155 induces EGFR suppression in pancreatic cancer cells.
    Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
    PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.
    Bharti R; Dey G; Ojha PK; Rajput S; Jaganathan SK; Sen R; Mandal M
    Oncogene; 2016 Jul; 35(30):3965-75. PubMed ID: 26616855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docoxahexaenoic Acid Induces Apoptosis of Pancreatic Cancer Cells by Suppressing Activation of STAT3 and NF-κB.
    Park M; Lim JW; Kim H
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
    Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
    Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
    Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
    Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
    Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis and G2/M cell cycle arrest induced by a timosaponin A3 from Anemarrhena asphodeloides Bunge on AsPC-1 pancreatic cancer cells.
    Kim Y; Kim KH; Lee IS; Park JY; Na YC; Chung WS; Jang HJ
    Phytomedicine; 2019 Mar; 56():48-56. PubMed ID: 30668353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.